Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
At Creative Biolabs, cutting-edge platforms enable us to provide our global customers with comprehensive, high-quality AR-targeted recombinant antibody products. Our commitment is to promote research and discovery by providing unparalleled technical support and exceptional value, ensuring that our customers achieve their scientific goals in a timely and efficient manner.
The androgen receptor (AR) is a key nuclear transcription factor belonging to the steroid hormone nuclear receptor family. It is activated by androgens like testosterone and dihydrotestosterone and is found in various tissues. AR plays crucial roles in the reproductive, musculoskeletal, cardiovascular, immune, neural, and hematopoietic systems. AR signaling is also implicated in the development of tumors in organs such as the prostate, bladder, liver, kidney, and lung, with a particularly strong association with prostate cancer. Consequently, targeting AR holds significant promise for treating prostate cancer and other malignancies.
Androgen receptor; NR3C4; nuclear receptor subfamily 3 group C member 4; AIS, AR8, DHTR, HUMARA, HYSP1, KD, NR3C4, SBMA, SMAX1, TFM, androgen receptor; Dihydrotestosterone receptor; Spinal And Bulbar Muscular Atrophy; Testicular Feminization; Kennedy Disease.
Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Plasma proteins, Transcription factors
Intracellular
Cell type enhanced (Hepatocytes, Granulosa cells, Breast glandular cells, Peritubular cells, Leydig cells, Skeletal myocytes)
Not detected in immune cells
Cell line enhanced (AF22, BJ hTERT+, HAP1, LHCN-M2, RH-30, T-47d)
Binds DNA as a homodimer. Part of a ternary complex containing AR, EFCAB6/DJBP and PARK7. Interacts with HIPK3 and NR0B2 in the presence of androgen. The ligand binding domain interacts with KAT7/HBO1 in the presence of dihydrotestosterone. Interacts with EFCAB6/DJBP, PQBP1, RANBP9, RBAK, SPDEF, SRA1, TGFB1I1 and RREB1. Interacts with ZMIZ1/ZIMP10 and ZMIZ2/ZMIP7 which both enhance its transactivation activity. Interacts with SLC30A9 and RAD54L2/ARIP4. Interacts with MACROD1 (via macro domain) (PubMed:19022849). Interacts via the ligand-binding domain with LXXLL and FXXLF motifs from NCOA1, NCOA2, NCOA3, NCOA4 and MAGEA11. The AR N-terminal poly-Gln region binds Ran resulting in enhancement of AR-mediated transactivation. Ran-binding decreases as the poly-Gln length increases. Interacts with HIP1 (via coiled coil domain). Interacts (via ligand-binding domain) with TRIM68. Interacts with TNK2. Interacts with USP26. Interacts with RNF6. Interacts (regulated by RNF6 probably through polyubiquitination) with RNF14; regulates AR transcriptional activity. Interacts with PRMT2 and TRIM24. Interacts with RACK1. Interacts with RANBP10; this interaction enhances dihydrotestosterone-induced AR transcriptional activity. Interacts with PRPF6 in a hormone-independent way; this interaction enhances dihydrotestosterone-induced AR transcriptional activity. Interacts with STK4/MST1. Interacts with ZIPK/DAPK3. Interacts with LPXN. Interacts with MAK. Part of a complex containing AR, MAK and NCOA3. Interacts with CRY1. Interacts with CCAR1 and GATA2. Interacts with ZNF318 (By similarity). Interacts with BUD31 (PubMed:25091737). Interacts with ARID4A (PubMed:23487765). Interacts with ARID4B (By similarity). Interacts (via NR LBD domain) with ZBTB7A; the interaction is direct and androgen-dependent (PubMed:20812024). Interacts with NCOR1 (PubMed:20812024). Interacts with NCOR2 (PubMed:20812024). Interacts with CRY2 in a ligand-dependent manner (By similarity).
Activator, DNA-binding, Receptor
Based on our advanced platforms, our seasoned research team develops and provides various innovative and high-quality anti-AR recombinant antibody products. Robust quality control and top-notch technical support work together to empower our anti-AR recombinant antibody products to be applied to customers’ meaningful projects with exceptional value.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MRO-0092-CN | Rabbit Anti-AR Recombinant Antibody (clone CBACN-027) | Human | Rabbit IgG | WB, IF, IHC, FC |
MOB-1873z | Mouse Anti-AR Recombinant Antibody (clone 15B4) | Human | Mouse IgG1 | WB, ELISA, FC, ICC, IF, IHC |
MOR-0226 | Hi-Affi™ Rabbit Anti-AR Recombinant Antibody (clone DS226AB) | Human | Rabbit IgG | ICC, IHC-P, IP, WB |
VS-0923-FY12 | Recombinant Mouse Anti-AR Antibody | Human | Mouse IgG2a | ELISA, WB |
ZG-0586F | Mouse Anti-AR Recombinant Antibody (clone F39.4.1) | Human | Mouse IgG1 | Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin |
Our commitment to the biopharmaceutical community shines through in our unwavering dedication to supporting research and development. We ensure superior product quality and unmatched customer support. By adhering to a meticulous quality control system, we guarantee complete customer satisfaction. Our products are engineered to surpass industry standards, facilitating the efficient development of medications and delivering exceptional value to our customers.
Fig.1 Anti-AR Recombinant Antibody in WB.
(Cat# ZG-0548J, Creative Biolabs).
Fig.2 Anti-AR Recombinant Antibody in IHC.
(Cat# ZG-0548J, Creative Biolabs).
Fig.3 Anti-AR Recombinant Antibody in IHC.
(Cat# ZG-0548J, Creative Biolabs).
Fig.4 Anti-AR Recombinant Antibody in IHC.
(Cat# ZG-0549J, Creative Biolabs).
Fig.5 Anti-AR Recombinant Antibody in IHC.
(Cat# ZG-0031J, Creative Biolabs).
Fig.6 Anti-AR Recombinant Antibody in WB.
(Cat# ZG-0307F, Creative Biolabs).
Our innovative serum-free mammalian cell expression system provides complete services from gene synthesis to scalable, premium anti-AR recombinant antibody generation. Having more than five years of process optimization experience, we provide fast and reasonably priced options for quickly varying antibody supply in a short turnaround.
Featured Anti-AR Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-AR recombinant antibody production.
Fig.8 Gram-scale anti-AR recombinant antibody production.
Creative Biolabs is committed to providing researchers with a wide range of innovative recombinant antibodies to aid in therapeutics development. We offer a wide range of anti-AR recombinant antibodies in different formats, including full-length, Fab, scFv, and more. With our deep knowledge and vast experience in antibody engineering, we are fully equipped to offer tailored solutions that cater to your unique research requirements.
Fig.9 Full-Length Anti-AR Recombinant Antibody Production and Modalities
Table 1. AR-targeted drug information (under development).
Company | Highest Phase | Classification | Condition |
ANI Pharmaceuticals BioSante (ANI Pharmaceuticals) Halozyme (Originator) Teva |
Registered - 2012 |
Androgens Steroids |
Cognitive disorders Hormone replacement therapy Hypogonadism Sexual dysfunction, female |
Barrier Therapeutics (Stiefel) Stiefel (Originator) |
Phase III |
Cancer Hormone Therapy Corticosteroids Fixed-Dose Combinations Imidazoles, Antifungal Agents Steroids |
Seborrheic dermatitis |
Lipocine (Originator) Verity Pharmaceuticals |
Phase II | Prodrugs | Hypogonadism |
Lilly (Originator) | Phase II | Fixed-Dose Combinations | Erectile dysfunction |
Acerus Pharmaceuticals Trimel Pharmaceuticals (Acerus Pharmaceuticals) |
Phase II |
Androgens Steroids |
Anorgasmia, female |
Merck & Co (Originator) | Phase II |
Androgens Fixed-Dose Combinations Progestogens Steroids |
Contraception, male |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Table 2. AR-targeted drug information (launched).
Company | Highest Phase | Drug Type | Condition |
Blue Water Vaccines Veru (Originator) |
Launched - 2022 |
Cancer Hormone Therapy Fixed-Dose Combinations Steroids |
Prostatic hyperplasia, benign |
Ferring (Originator) | Launched - 2018 |
Androgens Steroids |
Hormone replacement therapy Hypogonadism |
Cadila Healthcare (d/b/a Zydus Cadila) (Zydus) Merck & Co. (Merck & Co) Merck Sharp & Dohme (MSD) (Originator) |
Launched |
Androgens Fixed-Dose Combinations Steroids |
Hormone replacement therapy |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Please contact us during your leisure time for more information on our anti-AR recombinant antibody products. Our team is excited about the prospect of working with you to advance your research and identify potential opportunities for mutual benefit.